[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-366629-105":59,"doc-detail-366629-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","genomics-of-cervical-vulvar-and-vaginal-cancers-and-the-potential-of-precision-medicine-therapeutic-advances-in-medical-oncology-review","Genomics of Cervical, Vulvar and Vaginal Cancers and the Potential of Precision Medicine - Therapeutic advances in Medical Oncology Review","","Most cases of cervical cancer are driven by persistent infection with high-risk human papillomavirus (HPV) variants, which also contributes to about 30% of vulvar and 76% of vaginal malignancies. While HPV vaccination reduces high-grade pre-cancerous lesions, these cancers can still develop and therapeutic options remain limited. Molecular studies aim to identify targeted agents: initial combinations may include chemoradiotherapy, anti-angiogenics and immune checkpoint inhibitors, then tailor further therapy to tumor genomic profiles, including HER2- and other pathway-directed approaches, plus antibody-drug conjugates.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/genomics-of-cervical-vulvar-and-vaginal-cancers-and-the-potential-of-precision-medicine-therapeutic-advances-in-medical-oncology-review/366629/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/genomics-of-cervical-vulvar-and-vaginal-cancers-and-the-potential-of-precision-medicine-therapeutic-advances-in-medical-oncology-review/366629.png","ImageObject",300,407,{"name":92,"@type":93},"Mary Man","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-05","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What are the main drivers of cervical cancer and how do they relate to vulvar and vaginal cancers?","Question",{"text":112,"@type":113},"Most cervical cancer cases result from persistent infection with high-risk HPV variants. These variants also drive a substantial fraction of vulvar and vaginal malignancies.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Why do current treatment options remain limited for cervical, vulvar and vaginal cancers?",{"text":117,"@type":113},"Cancers can still develop even with or without HPV integration, and available treatments are more limited compared with more common cancers.",{"name":119,"@type":110,"acceptedAnswer":120},"How does the review propose selecting therapies for these cancers?",{"text":121,"@type":113},"It recommends starting with rational combination regimens and then tailoring therapy based on each tumor’s molecular profile, including targeted inhibitors and HER2-directed and antibody-drug conjugate options in appropriate contexts.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},366629,1790197285,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},7421720224475,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","TherapeuTic advances in  \nMedical Oncology Review  \nGenomics of cervical, vulvar and vaginal cancers and the potential of precision medicine  \nHolly E. Barker, Joseph Polidano, Andrew Jarratt and Clare L. Scott  \nAbstract: Most cases of cervical cancer are still caused by persistent infection with highrisk human papillomavirus (HPV) variants, which also drives the development of ~30% of vulvar and ~76% of vaginal malignancies. Implementation of HPV vaccination has significantly decreased the incidence of high-grade pre-cancerous cervical, vulvar and vaginal lesions. However, cervical, vulvar and vaginal cancers can still develop (with or without HPV integration) and treatment options are limited compared to more common cancers. As with many other cancer types, molecular studies should identify targeted agents that could be added to treatment regimens to improve response rates and survival. Combination regimens involving chemoradiotherapy, anti-angiogenics and immune checkpoint inhibitors should be considered in the first instance. Then, depending on the molecular profile of a particular tumour, more targeted therapies should be considered. In particular, HER2-targeted therapies are likely to be a viable treatment option for many individuals, including those with cervical adenocarcinoma of gastric-type and vulvar Paget’s disease. In cervical cancer, TGFβ , PI3K, ATR and PARP inhibitors have shown some benefit and warrant further investigation. In vulvar cancer, combination therapies involving EGFR inhibitors require ongoing evaluation. In vaginal cancer, combination therapies targeting the PI3K and MAPK pathways should be investigated for squamous cell carcinoma and melanoma, respectively. Finally, with the rapid expansion of antibody-drug conjugates in recent years, this is an especially exciting area of investigation. For cervical, vulvar and vaginal cancers specifically, trastuzumab deruxtecanand tisotumab vedotin could be important therapeutic options in the right context. In this review, we describe the molecular features of different cervical, vulvar and vaginal cancer types, current genomically-matched therapies being investigated and discuss treatment strategies with future potential.  \nPlain language summary  \nInvestigating the potential of matching drugs to specific changes in the DNA in cervical, vulvar and vaginal cancers  \nMost cases of cervical cancer are still caused by persistent infection with high-risk human papilloma virus (HPV) variants, which also drives the development of ~30% of vulvarand ~76% of vaginal malignancies. HPV vaccination has been an important preventative mechanism for these types of malignancies, however, they can still arise (with or without HPV infection) . Treatment options for cervical, vulvar and vaginal cancers are still limited compared to more common cancers. Investigating changes in the DNA in a particular tumour may indicate therapeutic options involving targeted agents (specific for the DNA alterations) . Clinical trials have been developed to test responses to some of these targeted agents in tumours carrying the relevant DNA alterations. Results from these  \nTherAdv Med Oncol 2025, Vol. 17: 1–29  \nDOI: 10. 1177/  \n17588359251363499 © The Author(s), 2025. Article reuse guidelines:  \n[sagepub.com/journals](sagepub.com/journals)permissions  \nCorrespondence to:  \nHolly E. Barker  \nCancer Biology and Stem Cells Division, Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, VIC 3052, Australia Department of Medical Biology, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Melbourne, VIC, Australia  \n[barker.h@wehi.edu.au](barker.h@wehi.edu.au)  \nJoseph Polidano Andrew Jarratt  \nWalter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia  \nDepartment of Medical Biology, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Melbourne, VIC, Australia  \nClare L. Scott  \nWalter and Eli","cbCaidl7HktGmHAA","https://ap.wps.com/l/cbCaidl7HktGmHAA","pdf",644479,29,"English","# Abstract\n# Plain language summary\n# Background of cervical, vulvar and vaginal cancer\n## Incidence","[{\"question\":\"What are the main drivers of cervical cancer and how do they relate to vulvar and vaginal cancers?\",\"answer\":\"Most cervical cancer cases result from persistent infection with high-risk HPV variants. These variants also drive a substantial fraction of vulvar and vaginal malignancies.\"},{\"question\":\"Why do current treatment options remain limited for cervical, vulvar and vaginal cancers?\",\"answer\":\"Cancers can still develop even with or without HPV integration, and available treatments are more limited compared with more common cancers.\"},{\"question\":\"How does the review propose selecting therapies for these cancers?\",\"answer\":\"It recommends starting with rational combination regimens and then tailoring therapy based on each tumor’s molecular profile, including targeted inhibitors and HER2-directed and antibody-drug conjugate options in appropriate contexts.\"}]","Genomics of Cervical, Vulvar and Vaginal Cancers and the Potential of Precision Medicine - Therapeutic advances in Medical Oncology Review | PDF",1790166493,73,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/60fbff534b64229d5a7712731620c117.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dc45249370915d7bdeb5c723c1c9e994.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fcb533cc1d8ea6e060fca067ae0e1d28.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9118d4b9a41d075ee308908289130da0.webp",980,1306]